- Home
- DECK vs ILMN Comparison
DECK vs ILMN Comparison
Compare DECK & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DECK
- ILMN
- Stock Information
- Founded
- DECK 1973
- ILMN 1998
- Country
- DECK United States
- ILMN United States
- Employees
- DECK N/A
- ILMN N/A
- Industry
- DECK Shoe Manufacturing
- ILMN Medical Specialities
- Sector
- DECK Consumer Discretionary
- ILMN Health Care
- Exchange
- DECK Nasdaq
- ILMN Nasdaq
- Market Cap
- DECK 15.7B
- ILMN 15.9B
- IPO Year
- DECK 1993
- ILMN 2000
- Fundamental
- Price
- DECK $105.67
- ILMN $71.20
- Analyst Decision
- DECK Buy
- ILMN Buy
- Analyst Count
- DECK 19
- ILMN 18
- Target Price
- DECK $211.44
- ILMN $139.50
- AVG Volume (30 Days)
- DECK 3.8M
- ILMN 2.6M
- Earning Date
- DECK 05-22-2025
- ILMN 05-08-2025
- Dividend Yield
- DECK N/A
- ILMN N/A
- EPS Growth
- DECK 33.68
- ILMN N/A
- EPS
- DECK 6.15
- ILMN N/A
- Revenue
- DECK $4,923,590,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- DECK $18.13
- ILMN $0.09
- Revenue Next Year
- DECK $10.48
- ILMN $4.71
- P/E Ratio
- DECK $17.19
- ILMN N/A
- Revenue Growth
- DECK 19.52
- ILMN N/A
- 52 Week Low
- DECK $93.72
- ILMN $68.70
- 52 Week High
- DECK $223.98
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- DECK 40.31
- ILMN 34.18
- Support Level
- DECK $101.69
- ILMN $68.70
- Resistance Level
- DECK $113.30
- ILMN $76.16
- Average True Range (ATR)
- DECK 7.47
- ILMN 4.18
- MACD
- DECK 0.94
- ILMN 0.38
- Stochastic Oscillator
- DECK 46.92
- ILMN 17.78
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2024, Ugg and Hoka accounted for 52% and 42% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships, but also operates e-commerce in more than 50 countries and about 178 company-operated stores. It generated 67% of its fiscal 2024 sales in the United States.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.